A carregar...
Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A
Emicizumab is a bispecific, humanized, monoclonal antibody mimicking the factor (F) VIII cofactor activity in mediating the generation of FXa by FIXa in patients with hemophilia A (HA). This subcutaneous non-factor agent has been recently extensively approved for the prophylaxis of patients of HA pa...
Na minha lista:
| Publicado no: | Drug Des Devel Ther |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7007498/ https://ncbi.nlm.nih.gov/pubmed/32099331 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S167731 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|